A detailed history of Nuveen Asset Management, LLC transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 112,483 shares of YMAB stock, worth $1.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
112,483
Previous 112,483 -0.0%
Holding current value
$1.25 Million
Previous $1.36 Million 8.69%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$11.6 - $17.25 $1.8 Million - $2.68 Million
-155,247 Reduced 57.99%
112,483 $1.36 Million
Q1 2024

May 13, 2024

SELL
$6.57 - $18.69 $868,619 - $2.47 Million
-132,210 Reduced 33.06%
267,730 $4.35 Million
Q4 2023

Feb 14, 2024

BUY
$4.88 - $7.42 $202,720 - $308,234
41,541 Added 11.59%
399,940 $2.73 Million
Q3 2023

Nov 14, 2023

SELL
$4.86 - $7.23 $322,859 - $480,303
-66,432 Reduced 15.64%
358,399 $1.95 Million
Q2 2023

Aug 14, 2023

BUY
$5.68 - $10.34 $519,373 - $945,479
91,439 Added 27.43%
424,831 $2.88 Million
Q1 2023

May 15, 2023

BUY
$2.83 - $5.11 $649,001 - $1.17 Million
229,329 Added 220.38%
333,392 $1.67 Million
Q4 2022

Feb 14, 2023

BUY
$3.0 - $15.17 $297 - $1,501
99 Added 0.1%
104,063 $508,000
Q3 2022

Nov 14, 2022

SELL
$13.96 - $19.67 $56,705 - $79,899
-4,062 Reduced 3.76%
103,964 $1.5 Million
Q2 2022

Aug 15, 2022

BUY
$8.22 - $15.13 $10,324 - $19,003
1,256 Added 1.18%
108,026 $1.63 Million
Q1 2022

May 16, 2022

BUY
$6.55 - $17.42 $8,259 - $21,966
1,261 Added 1.2%
106,770 $1.26 Million
Q4 2021

Feb 14, 2022

SELL
$15.51 - $29.31 $538,259 - $1.02 Million
-34,704 Reduced 24.75%
105,509 $1.62 Million
Q3 2021

Nov 12, 2021

SELL
$27.47 - $37.31 $588,187 - $798,881
-21,412 Reduced 13.25%
140,213 $4 Million
Q2 2021

Aug 16, 2021

BUY
$25.45 - $37.64 $847,179 - $1.25 Million
33,288 Added 25.94%
161,625 $5.46 Million
Q1 2021

May 17, 2021

BUY
$29.16 - $51.96 $57,357 - $102,205
1,967 Added 1.56%
128,337 $3.88 Million
Q4 2020

May 17, 2021

SELL
$37.86 - $54.26 $477,944 - $684,978
-12,624 Reduced 9.08%
126,370 $6.26 Million
Q4 2020

Feb 16, 2021

BUY
$37.86 - $54.26 $746,788 - $1.07 Million
19,725 Added 16.54%
138,994 $6.88 Million
Q3 2020

Nov 16, 2020

SELL
$35.13 - $43.62 $1.14 Million - $1.42 Million
-32,461 Reduced 21.39%
119,269 $4.58 Million
Q2 2020

Aug 14, 2020

BUY
$23.66 - $49.53 $1.04 Million - $2.18 Million
43,950 Added 40.78%
151,730 $6.56 Million
Q1 2020

May 14, 2020

BUY
$14.39 - $35.8 $32,679 - $81,301
2,271 Added 2.15%
107,780 $2.81 Million
Q4 2019

Feb 14, 2020

BUY
$23.81 - $33.78 $506,057 - $717,960
21,254 Added 25.23%
105,509 $3.3 Million
Q3 2019

Nov 14, 2019

BUY
$21.57 - $31.37 $93,980 - $136,679
4,357 Added 5.45%
84,255 $2.2 Million
Q2 2019

Aug 15, 2019

BUY
$19.51 - $28.31 $1.56 Million - $2.26 Million
79,898 New
79,898 $1.83 Million

Others Institutions Holding YMAB

About Y-mAbs Therapeutics, Inc.


  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $487M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.